Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Vaginal Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Vaginal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Vaginal Cancer

Antineoplastic Agents

All Drugs and Chemicals

Cisplatin

All patients with vaginal cancer will undergo radiochemotherapy (45 Gy on pelvis and tumor in association with cisplatinum) plus interventional radiotherapy (28 Gy on residual disease) with exclusive intent

Radiochemotherapy plus interventional radiotherapy

VALENTINA LANCELLOTTA, MD

VALENTINA LANCELLOTTA

Prospective observational multicenter study, aimed at evaluating the effectiveness on local control and cancer-specific survival of radiochemotherapy followed by interventional radiotherapy in patients affected by vaginal cancer

Prospective observational multicenter study, aimed at evaluating the effectiveness on local control and cancer-specific survival of radiochemotherapy (45Gy on pelvis and tumor plus chemotherapy with cisplatinum) followed by interventional radiotherapy (28Gy on residual tumor) in patients affected by vaginal cancer

Radiochemotherapy and Interventional Radiotherapy in Vaginal Cancer

Radiochemotherapy Treatment Followed by Interventional Radiotherapy in Patients Affected by Vagina Carcinoma Multi-centric Prospective Observational Study Trimodal Definitive Invasive Vaginal Carcinoma Treatment

Local control, the Cox regression model and multivariable logistic analysis will be used to analyze the role of clinical-pathological parameters as prognostic and predictive factors of pathological response to treatment

The Cox regression model and multivariable logistic analysis will be used to analyze the role of clinical-pathological parameters as prognostic and predictive factors of pathological response to treatment

The safety and tolerability profile of the treatment will be defined by the frequency and severity of adverse reactions as well as their possible correlation with the treatment received.

Anova for repeated measures or the corresponding non-parametric Friedman test will be used to identify changes in quality of life over time.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Radiochemotherapy and Interventional Radiotherapy in Vaginal Cancer	NCT06314568	Vaginal Cancer	Radiochemothera...	18 Years -	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Radiochemotherapy and Interventional Radiotherapy in Vaginal Cancer	NCT06314568	Vaginal Cancer	Radiochemothera...	18 Years -	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Radiochemotherapy and Interventional Radiotherapy in Vaginal Cancer	NCT06314568	Vaginal Cancer	Radiochemothera...	18 Years -	Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Spots Global Cancer Trial Database for radiochemotherapy plus interventional radiotherapy